Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors

European Journal of Pharmacology

Volumn 533, Issue 1-3, 2006, Pages 182-194

  Groneberg, David A ^a,b   Rabe, Klaus F ^c   Fischer, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokine; Lung; Tachykinin; VIP

Indexed keywords

BRONCHODILATING AGENT; CALCITONIN GENE RELATED PEPTIDE; FORMOTEROL; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; NEUROTROPHIN; OPIATE; RO 251392; RO 251553; TACHYKININ; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ABSENCE OF SIDE EFFECTS; ASTHMA; BLOOD VESSEL TONE; BRONCHIAL ARTERY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; IC 50; LUNG BLOOD VESSEL; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PULMONARY ARTERY; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; SUBMUCOSA; TRACHEOBRONCHIAL TREE; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; LUNG; MUCUS; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RESPIRATORY MUCOSA; T-LYMPHOCYTES; VAGUS NERVE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION;

EID: 33644814142     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.055     Document Type: Review

References (171)

1. J. Aliakbari, S.P. Sreedharan, C.W. Turck, and E.J. Goetzl Selective localization of vasoactive intestinal peptide and substance P in human eosinophils Biochem. Biophys. Res. Commun. 148 1987 1440 1445
2. R.J. Altiere, and L. Diamond Comparison of vasoactive intestinal peptide and isoproterenol relaxant effects in isolated cat airways J. Appl. Physiol. 56 1984 986 992
3. R.J. Altiere, M. Kung, and L. Diamond Comparative effects of inhaled isoproterenol and vasoactive intestinal peptide on histamine-induced bronchoconstriction in human subjects Chest 86 1984 153 154
4. M. Andersson, M. Carlquist, M. Maletti, and J.C. Marie Simultaneous solubilization of high-affinity receptors for VIP and glucagon and of a low-affinity binding protein for VIP, shown to be identical to calmodulin FEBS Lett. 318 1993 35 40
5. J.M. Anto, P. Vermeire, J. Vestbo, and J. Sunyer Epidemiology of chronic obstructive pulmonary disease Eur. Respir. J. 17 2001 982 994
6. S. Audigier, C. Barberis, and S. Jard Vasoactive intestinal polypeptide increases inositol phospholipid breakdown in the rat superior cervical ganglion Brain Res. 376 1986 363 367
7. S. Baldacci, E. Omenaas, and M.P. Oryszczyn Allergy markers in respiratory epidemiology Eur. Respir. J. 17 2001 773 790
8. J.N. Baraniuk, J.D. Lundgren, M. Okayama, J. Mullol, M. Merida, J.H. Shelhamer, and M.A. Kaliner Vasoactive intestinal peptide in human nasal mucosa J. Clin. Invest. 86 1990 825 831
9. P.J. Barnes, and C.M. Dixon The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans Am. Rev. Respir. Dis. 130 1984 162 166
10. P.J. Barnes, A. Cadieux, J.R. Carstairs, B. Greenberg, J.M. Polak, and K. Rhoden Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography Br. J. Pharmacol. 89 1986 157 162
11. P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur. Respir. J. 22 2003 672 688
12. M.G. Belvisi Sensory nerves and airway inflammation: role of A delta and C-fibres Pulm. Pharmacol. Ther. 16 2003 1 7
13. H.I. Berisha, M. Bratut, Y. Bangale, G. Colasurdo, S. Paul, and S.I. Said New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody Pulm. Pharmacol. Ther. 15 2002 121 127
14. D.R. Bolin, J. Cottrell, R. Garippa, N. O'Neill, B. Simko, and M. O'Donnell Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs Int. J. Pept. Protein Res. 41 1993 124 132
15. D.R. Bolin, J. Cottrell, R. Garippa, J. Michalewsky, N. Rinaldi, B. Simko, and M. O'Donnell Structure-activity studies on the vasoactive intestinal peptide pharmacophore. 1. Analogs of tyrosine Int. J. Pept. Protein Res. 46 1995 279 289
16. D.R. Bolin, J. Cottrell, R. Garippa, N. Rinaldi, R. Senda, B. Simko, and M. O'Donnell Comparison of cyclic and linear analogs of vasoactive intestinal peptide Drug Des. Discov. 13 1996 107 114
17. S.A. Bryan, M.J. Leckie, J. Khan, T. Hansel, P.J. Barnes, B. O'Connor, V. Kanabar, S. Matti, S.T. Holgate, S.J. Warrington, M.J. Boyce, L. Renzetti, A. Rames, and J.A. Bock Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2149 2153
18. A. Bundgaard, S.D. Enehjelm, and S. Aggestrup Pretreatment of exercise-induced asthma with inhaled vasoactive intestinal peptide (VIP) Eur. J. Respir. Dis. Suppl. 128 1983 427 429
19. R. Busto, J.C. Prieto, G. Bodega, J. Zapatero, and I. Carrero Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung Peptides 21 2000 265 269
20. A.R. Cameron, C.F. Johnston, C.T. Kirkpatrick, and M.C. Kirkpatrick The quest for the inhibitory neurotransmitter in bovine tracheal smooth muscle Q. J. Exp. Physiol. 68 1983 413 426
21. E. Cano, and L.C. Mahadevan Parallel signal processing among mammalian MAPKs Trends Biochem. Sci. 20 1995 117 122
22. L.O. Cardell, R. Uddman, and L. Edvinsson Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma Eur. Respir. J. 7 1994 2169 2173
23. J.R. Carstairs, and P.J. Barnes Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung J. Pharmacol. Exp. Ther. 239 1986 249 255
24. G.H. Caughey, F. Leidig, N.F. Viro, and J.A. Nadel Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase J. Pharmacol. Exp. Ther. 244 1988 133 137
25. K.F. Chung Cytokines in chronic obstructive pulmonary disease Eur. Respir. J. Suppl. 34 2001 50s 59s
26. E. Ciccarelli, J.P. Vilardaga, P. De Neef, E. Di Paolo, M. Waelbroeck, A. Bollen, and P. Robberecht Properties of the VIP-PACAP type II receptor stably expressed in CHO cells Regul. Pept. 54 1994 397 407
27. S.J. Coles, S.I. Said, and L.M. Reid Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro Am. Rev. Respir. Dis. 124 1981 531 536
28. A. Couvineau, C. Rouyer-Fessard, D. Darmoul, J.J. Maoret, I. Carrero, E. Ogier-Denis, and M. Laburthe Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains Biochem. Biophys. Res. Commun. 200 1994 769 776
29. C.P. Cox, M.R. Lerner, J.J. Wells, and S.I. Said Inhaled vasoactive intestinal peptide (VIP) prevents bronchoconstriction induced by inhaled histamine Am. Rev. Respir. Dis. 127 1983 A249
30. E. Cutz, W. Chan, N.S. Track, A. Goth, and S.I. Said Release of vasoactive intestinal polypeptide in mast cells by histamine liberators Nature 275 1978 661 662
31. M. Delgado VIP: a very important peptide in T helper differentiation Trends Immunol. 24 2003 221 224
32. M. Delgado, and D. Ganea Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166 2001 2907 2912
33. M. Delgado, and D. Ganea Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation FASEB J. 17 2003 944 946
34. M. Delgado, C. Martinez, M.C. Johnson, R.P. Gomariz, and D. Ganea Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes J. Neuroimmunol. 68 1996 27 38
35. M. Delgado, E.J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D.E. Brenneman, R.P. Gomariz, and D. Ganea Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun J. Biol. Chem. 273 1998 31427 31436
36. M. Delgado, D. Pozo, C. Martinez, J. Leceta, J.R. Calvo, D. Ganea, and R.P. Gomariz Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies J. Immunol. 162 1999 2358 2367
37. M. Delgado, C. Abad, C. Martinez, J. Leceta, and R.P. Gomariz Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease Nat. Med. 7 2001 563 568
38. M. Delgado, C. Abad, C. Martinez, M.G. Juarranz, J. Leceta, D. Ganea, and R.P. Gomariz PACAP in immunity and inflammation Ann. N. Y. Acad. Sci. 992 2003 141 157
39. R.D. Dey, W.A. Shannon Jr., and S.I. Said Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects Cell Tissue Res. 220 1981 231 238
40. R.D. Dey, J. Hoffpauir, and S.I. Said Co-localization of vasoactive intestinal peptide- and substance P-containing nerves in cat bronchi Neuroscience 24 1988 275 281
41. L. Diamond, J.L. Szarek, M.N. Gillespie, and R.J. Altiere In vivo bronchodilator activity of vasoactive intestinal peptide in the cat Am. Rev. Respir. Dis. 128 1983 827 832
42. G.U. Di Maria, S. Bellofiore, and P. Geppetti Regulation of airway neurogenic inflammation by neutral endopeptidase Eur. Respir. J. 12 1998 1454 1462
43. P.R. Eynott, D.A. Groneberg, G. Caramori, I.M. Adcock, L.E. Donnelly, S. Kharitonov, P.J. Barnes, and K.F. Chung Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness Eur. J. Pharmacol. 452 2002 123 133
44. P.R. Eynott, N. Paavolainen, D.A. Groneberg, A. Noble, M. Salmon, P. Nath, S.Y. Leung, and K.F. Chung Role of nitric oxide in chronic allergen-induced airway cell proliferation and inflammation J. Pharmacol. Exp. Ther. 304 2003 22 29
45. S.G. Farmer, and J. Togo Effects of epithelium removal on relaxation of airway smooth muscle induced by vasoactive intestinal peptide and electrical field stimulation Br. J. Pharmacol. 100 1990 73 78
46. G.S. Filippatos, N. Gangopadhyay, O. Lalude, N. Parameswaran, S.I. Said, W. Spielman, and B.D. Uhal Regulation of apoptosis by vasoactive peptides Am. J. Physiol. Lung Cell. Mol. Physiol. 281 2001 L749 L761
47. T.C. Fischer, P. Hartmann, C. Loser, J. Springer, C. Peiser, Q.T. Dinh, A. Fischer, and D.A. Groneberg Abundant expression of vasoactive intestinal polypeptide receptor VPAC2 mRNA in human skin J. Invest. Dermatol. 117 2001 754 756
48. A. Fischer, G. Folkerts, P. Geppetti, and D.A. Groneberg Mediators of asthma: nitric oxide Pulm. Pharmacol. Ther. 15 2002 73 81
49. T.C. Fischer, Q.T. Dinh, C. Peiser, C. Loser, A. Fischer, and D.A. Groneberg Simultaneous detection of receptor mRNA and ligand protein in human skin tissues J. Cutan. Pathol. 29 2002 65 71
50. S.H. Francis, B.D. Noblett, B.W. Todd, J.N. Wells, and J.D. Corbin Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase Mol. Pharmacol. 34 1988 506 517
51. G.M. Franconi, P.D. Graf, S.C. Lazarus, J.A. Nadel, and G.H. Caughey Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret J. Pharmacol. Exp. Ther. 248 1989 947 951
52. E.K. Frandsen, G.A. Krishna, and S.I. Said Vasoactive intestinal polypeptide promotes cyclic adenosine 3′,5′-monophosphate accumulation in guinea-pig trachea Br. J. Pharmacol. 62 1978 367 369
53. P. Ganz, A.W. Sandrock, S.C. Landis, J. Leopold, M.A. Gimbrone Jr., and R.W. Alexander Vasoactive intestinal peptide: vasodilatation and cyclic AMP generation Am. J. Physiol. 250 1986 H755 H760
54. M.A. Ghatei, M.N. Sheppard, D.J. O'Shaughnessy, T.E. Adrian, G.P. McGregor, J.M. Polak, and S.R. Bloom Regulatory peptides in the mammalian respiratory tract Endocrinology 111 1982 1248 1254
55. E.J. Goetzl, S.P. Sreedharan, and C.W. Turck Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells J. Biol. Chem. 263 1988 9083 9086
56. E.J. Goetzl, S.P. Sreedharan, C.W. Turck, R. Bridenbaugh, and B. Malfroy Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11) Biochem. Biophys. Res. Commun. 158 1989 850 854
57. E.J. Goetzl, J.K. Voice, S. Shen, G. Dorsam, Y. Kong, K.M. West, C.F. Morrison, and A.J. Harmar Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide Proc. Natl. Acad. Sci. U. S. A. 98 2001 13854 13859
58. R.P. Gomariz, C. Martinez, C. Abad, J. Leceta, and M. Delgado Immunology of VIP: a review and therapeutical perspectives Curr. Pharm. Des. 7 2001 89 111
59. P. Gourlet, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht In vitro properties of a high affinity selective antagonist of the VIP1 receptor Peptides 18 1997 1555 1560
60. P. Gourlet, P. Vertongen, A. Vandermeers, M.C. Vandermeers-Piret, J. Rathe, P. De Neef, M. Waelbroeck, and P. Robberecht The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass Peptides 18 1997 403 408
61. B. Greenberg, K. Rhoden, and P.J. Barnes Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries Blood Vessels 24 1987 45 50
62. P. Gressens, J.M. Hill, I. Gozes, M. Fridkin, and D.E. Brenneman Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos Nature 362 1993 155 158
63. J.R. Grider, K.S. Murthy, J.G. Jin, and G.M. Makhlouf Stimulation of nitric oxide from muscle cells by VIP: prejunctional enhancement of VIP release Am. J. Physiol. 262 1992 G774 G778
64. D.A. Groneberg, F. Doring, P.R. Eynott, A. Fischer, and H. Daniel Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1 Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G697 G704
65. D.A. Groneberg, F. Doring, M. Nickolaus, H. Daniel, and A. Fischer Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia Neurosci. Lett. 304 2001 181 184
66. D.A. Groneberg, P. Hartmann, Q.T. Dinh, and A. Fischer Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways Lab. Invest. 81 2001 749 755
67. D.A. Groneberg, M. Nickolaus, J. Springer, F. Doring, H. Daniel, and A. Fischer Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake Am. J. Pathol. 158 2001 707 714
68. D.A. Groneberg, J. Springer, and A. Fischer Vasoactive intestinal polypeptide as mediator of asthma Pulm. Pharmacol. Ther. 14 2001 391 401
69. D.A. Groneberg, F. Doring, M. Nickolaus, H. Daniel, and A. Fischer Renal assimilation of short chain peptides: visualization of tubular peptide uptake Pharm. Res. 19 2002 1209 1214
70. D.A. Groneberg, F. Doring, S. Theis, M. Nickolaus, A. Fischer, and H. Daniel Peptide transport in the mammary gland: expression and distribution of PEPT2 mRNA and protein Am. J. Physiol. Endocrinol. Metab. 282 2002 E1172 E1179
71. D.A. Groneberg, P.R. Eynott, F. Doring, Q. Thai Dinh, T. Oates, P.J. Barnes, K.F. Chung, H. Daniel, and A. Fischer Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung Thorax 57 2002 55 60
72. D.A. Groneberg, P.R. Eynott, S. Lim, T. Oates, R. Wu, I. Carlstedt, P. Roberts, B. McCann, A.G. Nicholson, B.D. Harrison, and K.F. Chung Expression of respiratory mucins in fatal status asthmaticus and mild asthma Histopathology 40 2002 367 373
73. D.A. Groneberg, P.R. Eynott, T. Oates, S. Lim, R. Wu, I. Carlstedt, A.G. Nicholson, and K.F. Chung Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung Respir. Med. 96 2002 81 86
74. D.A. Groneberg, W. Heppt, A. Cryer, A. Wussow, C. Peiser, M. Zweng, Q.T. Dinh, C. Witt, and A. Fischer Toxic rhinitis-induced changes of human nasal mucosa innervation Toxicol. Pathol. 31 2003 326 331
75. D.A. Groneberg, W. Heppt, P. Welker, C. Peiser, Q.T. Dinh, A. Cryer, M. Zweng, C. Witt, and A. Fischer Aspirin-sensitive rhinitis associated changes in upper airway innervation Eur. Respir. J. 22 2003 986 991
76. D.A. Groneberg, C. Peiser, Q.T. Dinh, J. Matthias, P.R. Eynott, W. Heppt, I. Carlstedt, C. Witt, A. Fischer, and K.F. Chung Distribution of respiratory mucin proteins in human nasal mucosa Laryngoscope 113 2003 520 524
77. D.A. Groneberg, C. Witt, U. Wagner, K.F. Chung, and A. Fischer Fundamentals of pulmonary drug delivery Respir. Med. 97 2003 382 387
78. D.A. Groneberg, I.M. Adcock, H. Witt, G. Hansen, and J. Springer Smads as intracellular mediators of airway inflammation Exp. Lung Res. 30 2004 223 250
79. D.A. Groneberg, A. Fischer, K.F. Chung, and H. Daniel Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport Am. J. Respir. Cell Mol. Biol. 30 2004 251 260
80. D.A. Groneberg, U. Wagner, and K.F. Chung Mucus and fatal asthma Am. J. Med. 116 2004 66 67
81. Y. Hamasaki, T. Saga, M. Mojarad, and S.I. Said Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery Trans. Assoc. Am. Physicians 96 1983 406 411
82. J. Hanze, D.A. Groneberg, F. Rose, A. Hanisch, J. Dotsch, C. Peiser, W. Seeger, W. Rascher, A. Fischer, and F. Grimminger Genomic organization and regulation of a human 7-helix transmembrane receptor which is expressed in pulmonary epithelial cells and induced in hypoxia Biochem. Biophys. Res. Commun. 291 2002 1160 1165
83. A.J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J.R. Pisegna, S.R. Rawlings, P. Robberecht, S.I. Said, S.P. Sreedharan, S.A. Wank, and J.A. Waschek International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide Pharmacol. Rev. 50 1998 265 270
84. N.A. Hasaneen, H.D. Foda, and S.I. Said Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice Chest 124 2003 1067 1072
85. W. Heppt, C. Peiser, A. Cryer, Q.T. Dinh, M. Zweng, C. Witt, A. Fischer, and D.A. Groneberg Innervation of human nasal mucosa in environmentally triggered hyperreflectoric rhinitis J. Occup. Environ. Med. 44 2002 924 929
86. D.F. Horrobin New drug discovery techniques are not so revolutionary BMJ 322 2001 239
87. P.H. Howarth, R. Djukanovic, J.W. Wilson, S.T. Holgate, D.R. Springall, and J.M. Polak Mucosal nerves in endobronchial biopsies in asthma and non-asthma Int. Arch. Allergy Appl. Immunol. 94 1991 330 333
88. N. Inagaki, H. Yoshida, M. Mizuta, N. Mizuno, Y. Fujii, T. Gonoi, J. Miyazaki, and S. Seino Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells Proc. Natl. Acad. Sci. U. S. A. 91 1994 2679 2683
89. T. Ishihara, R. Shigemoto, K. Mori, K. Takahashi, and S. Nagata Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide Neuron 8 1992 811 819
90. O. Ito, and S. Tachibana Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity Peptides 12 1991 131 137
91. Y. Ito, and K. Takeda Non-adrenergic inhibitory nerves and putative transmitters in the smooth muscle of cat trachea J. Physiol. (Lond.) 330 1982 497 511
92. G.F. Joos, K.O. De Swert, and R.A. Pauwels Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists Eur. J. Pharmacol. 429 2001 239 250
93. G.F. Joos, W. Vincken, R. Louis, V.J. Schelfhout, J.H. Wang, M.J. Shaw, G.D. Cioppa, and R.A. Pauwels Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Eur. Respir. J. 23 2004 76 81
94. H.B. Kaltreider, S. Ichikawa, P.K. Byrd, D.A. Ingram, J.L. Kishiyama, S.P. Sreedharan, M.L. Warnock, J.M. Beck, and E.J. Goetzl Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma Am. J. Respir. Cell Mol. Biol. 16 1997 133 144
95. H. Kanazawa, T. Kawaguchi, S. Shoji, T. Fujii, S. Kudoh, K. Hirata, N. Kurihara, and J. Yoshikawa Synergistic effect of nitric oxide and vasoactive intestinal peptide on bronchoprotection against histamine in anesthetized guinea pigs Am. J. Respir. Crit. Care Med. 155 1997 747 750
96. S. Kerzel, G. Path, W.A. Nockher, D. Quarcoo, U. Raap, D.A. Groneberg, Q.T. Dinh, A. Fischer, A. Braun, and H. Renz Pan-neurotrophin receptor p75 contributes to neuronal hyperreactivity and airway inflammation in a murine model of experimental asthma Am. J. Respir. Cell Mol. Biol. 28 2003 170 178
97. P.J. Kingham, R.W. Costello, and W.G. McLean Eosinophil and airway nerve interactions Pulm. Pharmacol. Ther. 16 2003 9 13
98. J.C. Kips, K.G. Tournoy, and R.A. Pauwels New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5 Eur. Respir. J. 17 2001 499 506
99. A. Laitinen, M. Partanen, A. Hervonen, M. Pelto-Huikko, and L.A. Laitinen VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study Histochemistry 82 1985 313 319
100. L.A. Laitinen, A. Laitinen, R.O. Salonen, and J.G. Widdicombe Vascular actions of airway neuropeptides Am. Rev. Respir. Dis. 136 1987 S59 S64
101. S.C. Lazarus, C.B. Basbaum, P.J. Barnes, and W.M. Gold cAMP immunocytochemistry provides evidence for functional VIP receptors in trachea Am. J. Physiol. 251 1986 C115 C119
102. C.M. Lilly, J.M. Drazen, and S.A. Shore Peptidase modulation of airway effects of neuropeptides Proc. Soc. Exp. Biol. Med. 203 1993 388 404
103. C.M. Lilly, L. Kobzik, A.E. Hall, and J.M. Drazen Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs J. Clin. Invest. 93 1994 2667 2674
104. C.M. Lilly, T.R. Bai, S.A. Shore, A.E. Hall, and J.M. Drazen Neuropeptide content of lungs from asthmatic and nonasthmatic patients Am. J. Respir. Crit. Care Med. 151 1995 548 553
105. T.M. Lincoln, T.L. Cornwell, and A.E. Taylor cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells Am. J. Physiol. 258 1990 C399 C407
106. A. Linden, L. Hansson, A. Andersson, M. Palmqvist, P. Arvidsson, C.G. Lofdahl, P. Larsson, and J. Lotvall Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma Thorax 58 2003 217 221
107. S. Linder, T. Barkhem, A. Norberg, H. Persson, M. Schalling, T. Hokfelt, and G. Magnusson Structure and expression of the gene encoding the vasoactive intestinal peptide precursor Proc. Natl. Acad. Sci. U. S. A. 84 1987 605 609
108. J.M. Lundberg Evidence for coexistence of vasoactive intestinal polypeptide (VIP) and acetylcholine in neurons of cat exocrine glands. Morphological, biochemical and functional studies Acta Physiol. Scand., Suppl. 496 1981 1 57
109. J.M. Lundberg, T. Hokfelt, J. Kewenter, G. Pettersson, H. Ahlman, R. Edin, A. Dahlstrom, G. Nilsson, L. Terenius, K. Uvnas-Wallensten, and S. Said Substance P-, VIP-, and enkephalin-like immunoreactivity in the human vagus nerve Gastroenterology 77 1979 468 471
110. J.M. Lundberg, J. Fahrenkrug, T. Hokfelt, C.R. Martling, O. Larsson, K. Tatemoto, and A. Anggard Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man Peptides 5 1984 593 606
111. M.A. Lung, and J.G. Widdicombe Lung reflexes and nasal vascular resistance in the anaesthetized dog J. Physiol. (Lond.) 386 1987 465 474
112. A. Luts, and F. Sundler Peptide-containing nerve fibers in the respiratory tract of the ferret Cell Tissue Res. 258 1989 259 267
113. E.M. Lutz, W.J. Sheward, K.M. West, J.A. Morrow, G. Fink, and A.J. Harmar The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide FEBS Lett. 334 1993 3 8
114. R.K. Malhotra, T.D. Wakade, and A.R. Wakade Vasoactive intestinal polypeptide and muscarine mobilize intracellular Ca2+ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP3 in exocytosis J. Biol. Chem. 263 1988 2123 2126
115. S.C. Martin, and T.J. Shuttleworth Vasoactive intestinal peptide stimulates a cAMP-mediated CI- current in avian salt gland cells Regul. Pept. 52 1994 205 214
116. R. Matran, K. Alving, C.R. Martling, J.S. Lacroix, and J.M. Lundberg Effects of neuropeptides and capsaicin on tracheobronchial blood flow of the pig Acta Physiol. Scand. 135 1989 335 342
117. Y. Matsuzaki, Y. Hamasaki, and S.I. Said Vasoactive intestinal peptide: a possible transmitter of nonadrenergic relaxation of guinea pig airways Science 210 1980 1252 1253
118. A. Morice, R.J. Unwin, and P.S. Sever Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects Lancet 2 1983 1225 1227
119. R.F. Murphy, F.R., M. Chen, M. Vorhees, and S.N. Jafee Immunoreactivities of vasoactive intestinal peptide (VIP) and glucagon in leukocytes from leukaemic patients J. Lab. Clin. Med. 99 1981 294 295
120. P.A. Nandiwada, P.J. Kadowitz, S.I. Said, M. Mojarad, and A.L. Hyman Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat J. Appl. Physiol. 58 1985 1723 1728
121. I. Nathanson, J.H. Widdicombe, and P.J. Barnes Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium J. Appl. Physiol. 55 1983 1844 1848
122. D.A. Nio, R.N. Moylan, and J.K. Roche Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements J. Immunol. 150 1993 5281 5288
123. H. Obara, M. Kusunoki, M. Mori, K. Mikawa, and S. Iwai The effects of various peptides on the isolated pulmonary artery Peptides 10 1989 241 243
124. M. O'Donnell, R.J. Garippa, N.C. O'Neill, D.R. Bolin, and J.M. Cottrell Structure-activity studies of vasoactive intestinal polypeptide J. Biol. Chem. 266 1991 6389 6392
125. M. O'Donnell, R.J. Garippa, N. Rinaldi, W.M. Selig, B. Simko, L. Renzetti, S.A. Tannu, M.A. Wasserman, A. Welton, and D.R. Bolin Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: in vitro and in vivo bronchodilator studies J. Pharmacol. Exp. Ther. 270 1994 1282 1288
126. M. O'Donnell, R.J. Garippa, N. Rinaldi, W.M. Selig, J.E. Tocker, S.A. Tannu, M.A. Wasserman, A. Welton, and D.R. Bolin Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: effect on in vitro and in vivo models of pulmonary anaphylaxis J. Pharmacol. Exp. Ther. 270 1994 1289 1294
127. M.S. O'Dorisio, N.S. Hermina, T.M. O'Dorisio, and S.P. Balcerzak Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase J. Immunol. 127 1981 2551 2554
128. T. Ohzeki, N. Ishitani, K. Hanaki, H. Motozumi, H. Ohtahara, K. Fukushima, S. Nakai, M. Kishida, S. Kobayashi, and K. Shiraki Responses of plasma vasoactive intestinal polypeptide to methacholine and exercise loading in children and adolescents with bronchial asthma Pediatr. Allergy Immunol. 4 1993 26 29
129. S. Ollerenshaw, D. Jarvis, A. Woolcock, C. Sullivan, and T. Scheibner Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma N. Engl. J. Med. 320 1989 1244 1248
130. J.B. Palmer, F.M. Cuss, and P.J. Barnes VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways J. Appl. Physiol. 61 1986 1322 1328
131. J.B. Palmer, F.M. Cuss, J.B. Warren, M. Blank, S.R. Bloom, and P.J. Barnes Effect of infused vasoactive intestinal peptide on airway function in normal subjects Thorax 41 1986 663 666
132. S. Paul, S.I. Said, A.B. Thompson, D.J. Volle, D.K. Agrawal, H. Foda, and S. de la Rocha Characterization of autoantibodies to vasoactive intestinal peptide in asthma J. Neuroimmunol. 23 1989 133 142
133. A.C. Peatfield, P.J. Barnes, C. Bratcher, J.A. Nadel, and B. Davis Vasoactive intestinal peptide stimulates tracheal submucosal gland secretion in ferret Am. Rev. Respir. Dis. 128 1983 89 93
134. V. Petkov, W. Mosgoeller, R. Ziesche, M. Raderer, L. Stiebellehner, K. Vonbank, G.-C. Funk, G. Hamilton, C. Novotny, B. Burian, and L.-H. Block Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J. Clin. Invest. 111 2003 1339 1346
135. S.R. Rawlings, I. Piuz, W. Schlegel, J. Bockaert, and L. Journot Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs Endocrinology 136 1995 2088 2098
136. P.S. Richardson, and S.E. Webber The control of mucous secretion in the airways by peptidergic mechanisms Am. Rev. Respir. Dis. 136 1987 S72 S76
137. I. Rubio-Aliaga, I. Frey, M. Boll, D.A. Groneberg, H.M. Eichinger, R. Balling, and H. Daniel Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney Mol. Cell. Biol. 23 2003 3247 3252
138. T. Saga, and S.I. Said Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma Trans. Assoc. Am. Physicians 97 1984 304 310
139. S.I. Said Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide Exp. Lung Res. 3 1982 343 348
140. S.I. Said Vasoactive intestinal peptide: involvement of calmodulin and catalytic antibodies Neurochem. Int. 23 1993 215 219
141. S.I. Said, and V. Mutt Polypeptide with broad biological activity: isolation from small intestine Science 169 1970 1217 1218
142. S.I. Said, and V. Mutt Potent peripheral and splanchnic vasodilator peptide from normal gut Nature 225 1970 863 864
143. O. Sand, B. Chen, Q. Li, H.E. Karlsen, T. Bjoro, and E. Haug Vasoactive intestinal peptide (VIP) may reduce the removal rate of cytosolic Ca2+ after transient elevations in clonal rat lactotrophs Acta Physiol. Scand. 137 1989 113 123
144. T. Sata, J. Linden, L.W. Liu, E. Kubota, and S.I. Said Vasoactive intestinal peptide evokes endothelium-dependent relaxation and cyclic AMP accumulation in rat aorta Peptides 9 1988 853 858
145. D.T. Schmidt, E. Ruhlmann, B. Waldeck, D. Branscheid, A. Luts, F. Sundler, and K.F. Rabe The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery Naunyn-Schmiedeberg's Arch. Pharmacol. 364 2001 314 320
146. H. Sharaf, and S.I. Said Tracheal relaxant response to vasoactive intestinal peptide (VIP): influence of airway epithelium and peptidases (abstract) FASEB J. 7 1993 A686
147. R.K. Sharma, B.J. Addis, and P.K. Jeffery The distribution and density of airway vasoactive intestinal polypeptide (VIP) binding sites in cystic fibrosis and asthma Pulm. Pharmacol. 8 1995 91 96
148. S. Shimura, T. Sasaki, K. Ikeda, H. Sasaki, and T. Takishima VIP augments cholinergic-induced glycoconjugate secretion in tracheal submucosal glands J. Appl. Physiol. 65 1988 2537 2544
149. D. Spina, and C.P. Page Asthma - a need for a rethink? Trends Pharmacol. Sci. 23 2002 311 315
150. J. Springer, P. Geppetti, A. Fischer, and D.A. Groneberg Calcitonin gene-related peptide as inflammatory mediator Pulm. Pharmacol. Ther. 16 2003 121 130
151. J. Springer, S. Amadesi, M. Trevisani, S. Harrison, Q.T. Dinh, G.P. McGregor, A. Fischer, P. Geppetti, and D.A. Groneberg Effects of alpha calcitonin gene-related peptide in human bronchial smooth muscle and pulmonary artery Regul. Pept. 118 2004 127 134
152. S.P. Sreedharan, D.R. Patel, J.X. Huang, and E.J. Goetzl Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor Biochem. Biophys. Res. Commun. 193 1993 546 553
153. S.P. Sreedharan, J.X. Huang, M.C. Cheung, and E.J. Goetzl Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene Proc. Natl. Acad. Sci. U. S. A. 92 1995 2939 2943
154. D. Stallwood, C.H. Brugger, B.A. Baggenstoss, P.M. Stemmer, H. Shiraga, D.F. Landers, and S. Paul Identity of a membrane-bound vasoactive intestinal peptide-binding protein with calmodulin J. Biol. Chem. 267 1992 19617 19621
155. M. Svoboda, M. Tastenoy, J. Van Rampelbergh, J.F. Goossens, P. De Neef, M. Waelbroeck, and P. Robberecht Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts Biochem. Biophys. Res. Commun. 205 1994 1617 1624
156. E.K. Tam, G.M. Franconi, J.A. Nadel, and G.H. Caughey Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi Am. J. Respir. Cell Mol. Biol. 2 1990 449 452
157. H. Tang, A. Welton, and D. Ganea Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553 J. Interferon. Cytokine Res. 15 1995 993 1003
158. I. Tatsuno, T. Yada, S. Vigh, H. Hidaka, and A. Arimura Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide increase cytosolic free calcium concentration in cultured rat hippocampal neurons Endocrinology 131 1992 73 81
159. D.C. Thompson, L. Diamond, and R.J. Altiere Enzymatic modulation of vasoactive intestinal peptide and nonadrenergic noncholinergic inhibitory responses in guinea pig tracheae Am. Rev. Respir. Dis. 142 1990 1119 1123
160. B.J. Undem, E.C. Dick, and C.K. Buckner Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea-pig minced lung Eur. J. Pharmacol. 88 1983 247 250
161. T.B. Usdin, T.I. Bonner, and E. Mezey Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions
162. E. Van Ganse, L. Laforest, G. Pietri, J.P. Boissel, F. Gormand, R. Ben-Joseph, and P. Ernst Persistent asthma: disease control, resource utilisation and direct costs Eur. Respir. J. 20 2002 260 267
163. J.K. Voice, G. Dorsam, H. Lee, Y. Kong, and E.J. Goetzl Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor FASEB J. 15 2001 2489 2496
164. J.K. Voice, G. Dorsam, R.C. Chan, C. Grinninger, Y. Kong, and E.J. Goetzl Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide Regul. Pept. 109 2002 199 208
165. J.K. Voice, C. Grinninger, Y. Kong, Y. Bangale, S. Paul, and E.J. Goetzl Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice J. Immunol. 170 2003 308 314
166. U. Wagner, D. Bredenbroker, B. Storm, B. Tackenberg, H.C. Fehmann, and P. von Wichert Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea Peptides 19 1998 241 245
167. S.E. Webber, and J.G. Widdicombe The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea Br. J. Pharmacol. 91 1987 139 148
168. Y. Wei, and S. Mojsov Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology J. Neuroendocrinol. 8 1996 811 817
169. J.G. Widdicombe Autonomic regulation. i-NANC/e-NANC Am. J. Respir. Crit. Care Med. 158 1998 S171 S175
170. J.G. Widdicombe Overview of neural pathways in allergy and asthma Pulm. Pharmacol. Ther. 16 2003 23 30
171. M. Xia, S.P. Sreedharan, D.R. Bolin, G.O. Gaufo, and E.J. Goetzl Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor J. Pharmacol. Exp. Ther. 281 1997 629 633